Low volume, easy to manipulate
Management does not have a lot of positive news to report, thus there are no regular PRs to keep current investors buying or to attract new retail investors
Clinically- Slow enrollment
Changes in trial protocols
Getting trial sites ready to enroll pts
Trials started in 2009, then stopped until recently
First data release is over a year away
Modest sales throughout the world, in areas were the Mesh is currently available.
Positives:
In 2011, that is two years later, we were able to find 20 patients, bring back 20 patients and do follow-up angiograms. in all 20 of these angiograms, the Mesh treated vein graft showed no change from their initial follow-up angiogram, which were done approximately nine months after the patient bypass surgery.
This is of course, very, very encouraging.
- Clinical trial sites and CT surgeons are very well known as delivering top of the line and cutting edge care.
-High levels of attention and interest in the Mesh by a great number of institutions and surgeons through out the world.
A lot of potential here, but it has to be realized, to some degree to generate interest and investment.
News 
Market Data 
Discover 
AI
